Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in St. Ingbert – page 8

306 clinical trials in St. Ingbert, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
St. Ingbert at a glance
306
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

306 trials in St. Ingbert

Open in trial search

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Breast cancer

Recruiting

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:F. Hoffmann-La Roche AG

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study of Pozelimab and Cemdisiran for Adults with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study of accelerated chemoradiotherapy followed by durvalumab treatment in patients with locally advanced non-small-cell lung cancer (NSCLC) using PET imaging guidance

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:TheraOp gGmbH

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Busulfan
  • Sponsor:Medical Center - University Of Freiburg

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Study on the Effects of Cyclosporine A in Patients with Takotsubo Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Glioma

Recruiting

Study of Temozolomide and Lomustine Followed by Radiotherapy versus Standard Treatment in Patients with Newly Diagnosed Grade 2 or 3 Glioma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in St. Ingbert

What the registry says about research in the country

01 Cardiovascular Diseases

In St. Ingbert-Oberwürzbach, clinical research in cardiovascular diseases is focused on reducing heart-related risk and improving long-term outcomes for people with atherosclerotic cardiovascular disease and broader cardiovascular disease concerns.

  • Studies on protecting against major cardiovascular events such as heart attack and stroke
  • Research evaluating whether new treatments can lower cardiovascular risk alongside standard care
  • Trials examining cholesterol control in people with established heart and blood vessel disease

These trials aim to test whether newer therapies can improve prevention and treatment effectiveness in everyday care.

02 Nutritional and Metabolic Diseases

A second major research area is nutritional and metabolic diseases, with a strong emphasis on obesity, overweight, and type 2 diabetes.

  • Weight management studies for people living with obesity or excess body weight
  • Trials combining diabetes care with efforts to support healthier weight outcomes
  • Research looking at better approaches for long-term metabolic control

The overall goal is to explore treatments that can help people lose weight, maintain results, and reduce related health risks.

03 Diabetes and Glycaemic Control

Several studies are centered on diabetes, including type 1 diabetes and type 2 diabetes mellitus, with attention to improving blood sugar control and related complications.

  • Trials comparing new insulin strategies for people with type 1 diabetes
  • Research on glucose-lowering treatments for patients with type 2 diabetes and cardiovascular risk
  • Studies assessing the broader impact of diabetes therapies on long-term health

This work is designed to see whether newer treatment approaches can offer better control and support safer diabetes management.

04 Obesity and Weight Management

A large share of the local trial activity involves obesity and chronic weight management, reflecting strong interest in therapies that support meaningful and lasting weight reduction.

  • Studies testing new medicines for adults with obesity or overweight
  • Research focused on maintaining weight loss over time
  • Trials examining how weight reduction may also improve related metabolic health

These studies are intended to better understand how treatment can support healthier body weight and reduce associated complications.

05 Lipid Lowering and Cardiometabolic Risk

Some trials in Germany are investigating whether newer lipid-lowering approaches can better manage hypercholesterolemia and lower the risk of future heart problems.

  • Research comparing cholesterol-lowering options in people with cardiovascular disease
  • Studies assessing added benefit alongside standard treatment
  • Trials aimed at improving prevention of heart and vascular events

The focus is on finding more effective ways to reduce harmful cholesterol and protect long-term cardiovascular health.

06 Eye Health in Diabetes

One notable study area examines diabetic retinopathy in people with type 2 diabetes, exploring whether diabetes treatment can influence eye health over time.

  • Safety-focused research on long-term effects for diabetic eye disease
  • Studies using ophthalmic assessments to monitor progression
  • Work aimed at understanding how improved glucose control may affect eye complications

This research supports a better understanding of how diabetes therapies may shape both blood sugar control and vision-related outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.